Chinese Simcere Reports Fourth Quarter Sales Growth; Preparing For Health Care Reforms
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - China-based Simcere Pharmaceutical Group reported a spike in the sales of its two main products, anti-cancer drug Endu and injectable edaravone Bicun in its fourth quarter 2007 financial results.